What Is the Role of GLP-1 Receptor Agonists in the Treatment of MASLD?: A Literature Review

By Sweera A. Qari, Kay Samuel, Jonathan A. Fallowfield, Peter C. Hayes, Steven D. Morley, John N. Plevris

EMS300 Student Conference 2026

Slide 1: What is the Role of GLP-1 Receptor Agonists in the Treatment of MASLD?:. A full description follows.

Summary

The slide deck reviews the role of GLP-1 receptor agonists (GLP-1 RAs) in treating metabolic dysfunction-associated steatotic liver disease (MASLD). It highlights the prevalence of MASLD, particularly among adults and children, and discusses current treatment limitations. The methodology assesses whether GLP-1 RAs can reverse MASLD through weight-dependent or independent mechanisms. Findings indicate that GLP-1 RAs may improve hepatic steatosis and steatohepatitis, with some studies suggesting benefits even with minimal weight loss. Further research is recommended, particularly regarding their use in paediatric cases and cirrhosis.